Biomea Fusion Inc (BMEA) - Net Assets
Based on the latest financial reports, Biomea Fusion Inc (BMEA) has net assets worth $18.72 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($46.38 Million) and total liabilities ($27.67 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BMEA PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $18.72 Million |
| % of Total Assets | 40.36% |
| Annual Growth Rate | N/A |
| 5-Year Change | -83.47% |
| 10-Year Change | N/A |
| Growth Volatility | 1353.73 |
Biomea Fusion Inc - Net Assets Trend (2019–2025)
This chart illustrates how Biomea Fusion Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Biomea Fusion Inc (BMEA) market capitalisation.
Annual Net Assets for Biomea Fusion Inc (2019–2025)
The table below shows the annual net assets of Biomea Fusion Inc from 2019 to 2025. Also explore BMEA shareholders equity momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $29.55 Million | -42.70% |
| 2024-12-31 | $51.57 Million | -69.53% |
| 2023-12-31 | $169.24 Million | +55.92% |
| 2022-12-31 | $108.54 Million | -39.29% |
| 2021-12-31 | $178.78 Million | +3358.75% |
| 2020-12-31 | $5.17 Million | +24714.29% |
| 2019-12-31 | $-21.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biomea Fusion Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 44619700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | 0.02% |
| Other Components | $478.59 Million | 1619.49% |
| Total Equity | $29.55 Million | 100.00% |
Biomea Fusion Inc Competitors by Market Cap
The table below lists competitors of Biomea Fusion Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Drilling Tools International Corp.
NASDAQ:DTI
|
$86.06 Million |
|
DeFi Development Corp.
NASDAQ:DFDV
|
$86.14 Million |
|
Tomer Energy Royalties 2012 Ltd
TA:TOEN
|
$86.17 Million |
|
Veritone Inc
NASDAQ:VERI
|
$86.17 Million |
|
Transart Graphics Co Ltd
TW:8481
|
$86.03 Million |
|
RF Industries Ltd
NASDAQ:RFIL
|
$86.02 Million |
|
Pathfinder Bancorp Inc
NASDAQ:PBHC
|
$86.02 Million |
|
JLK Inc
KQ:322510
|
$85.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biomea Fusion Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 51,573,000 to 29,552,000, a change of -22,021,000 (-42.7%).
- Net loss of 61,797,000 reduced equity.
- New share issuances of 67,745,000 increased equity.
- Other factors decreased equity by 27,969,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-61.80 Million | -209.11% |
| Share Issuances | $67.75 Million | +229.24% |
| Other Changes | $-27.97 Million | -94.64% |
| Total Change | $- | -42.70% |
Book Value vs Market Value Analysis
This analysis compares Biomea Fusion Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.16x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.00 | $1.79 | x |
| 2020-12-31 | $0.48 | $1.79 | x |
| 2021-12-31 | $7.49 | $1.79 | x |
| 2022-12-31 | $3.71 | $1.79 | x |
| 2023-12-31 | $4.96 | $1.79 | x |
| 2024-12-31 | $1.43 | $1.79 | x |
| 2025-12-31 | $0.57 | $1.79 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biomea Fusion Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -209.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.98x
- Recent ROE (-209.11%) is below the historical average (-106.66%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.20 Million |
| 2020 | -103.00% | 0.00% | 0.00x | 12.10x | $-5.84 Million |
| 2021 | -23.05% | 0.00% | 0.00x | 1.04x | $-59.10 Million |
| 2022 | -73.73% | 0.00% | 0.00x | 1.19x | $-90.88 Million |
| 2023 | -69.28% | 0.00% | 0.00x | 1.18x | $-134.18 Million |
| 2024 | -268.41% | 0.00% | 0.00x | 1.55x | $-143.58 Million |
| 2025 | -209.11% | 0.00% | 0.00x | 1.98x | $-64.75 Million |
Industry Comparison
This section compares Biomea Fusion Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biomea Fusion Inc (BMEA) | $18.72 Million | 0.00% | 1.48x | $86.04 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About Biomea Fusion Inc
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase I… Read more